|
|
|
| Treatment & Prevention > Emerging Therapies |
|
Glucagon-like Peptide 1 Receptor Agonists: A Novel Treatment for Type 2 Diabetes
GLP-1 receptor agonists are an exciting, emerging therapeutic class, and they represent a novel approach to the treatment of type 2 diabetes. Because of the progressive nature of type 2 diabetes, the majority of patients will eventually need multiple agents to control their disease. This novel class represents another treatment option that has the potential to help patients with type 2 diabetes meet their glycemic goals with fewer side effects.
|
Emerging Therapies Overview
Several new classes of agents for treating patients with diabetes populate the landscape and include Peroxisome proliferator-activated receptor (PPAR) agonists that display dual agonist activity of PPAR alpha and gamma. For patients with diabetes, several potential new therapies exist, including inhaled insulin, oral insulin, buccal and nasal insulin, implanted peritoneal insulin infusion pumps, synthetic amylin, glucagon-like peptide-1 (GLP-1), and islet cell transplantation. Newer options for the treatment of patients with diabetic microvascular complications also exist in the form of protein kinase C beta inhibitors. Available details regarding the safety and efficacy profiles of these agents are presented here.
|
|
|
